%0 Journal Article %A Heather Kalish %A Carleen Klumpp-Thomas %A Sally Hunsberger %A Holly Ann Baus %A Michael P Fay %A Nalyn Siripong %A Jing Wang %A Jennifer Hicks %A Jennifer Mehalko %A Jameson Travers %A Matthew Drew %A Kyle Pauly %A Jacquelyn Spathies %A Tran Ngo %A Kenneth M. Adusei %A Maria Karkanitsa %A Jennifer A Croker %A Yan Li %A Barry I. Graubard %A Lindsay Czajkowski %A Olivia Belliveau %A Cheryl Chairez %A Kelly Snead %A Peter Frank %A Anandakumar Shunmugavel %A Alison Han %A Luca T. Giurgea %A Luz Angela Rosas %A Rachel Bean %A Rani Athota %A Adriana Cervantes-Medina %A Monica Gouzoulis %A Brittany Heffelfinger %A Shannon Valenti %A Rocco Caldararo %A Michelle M. Kolberg %A Andrew Kelly %A Reid Simon %A Saifullah Shafiq %A Vanessa Wall %A Susan Reed %A Eric W Ford %A Ravi Lokwani %A John-Paul Denson %A Simon Messing %A Sam G. Michael %A William Gillette %A Robert P. Kimberly %A Steven E. Reis %A Matthew D. Hall %A Dominic Esposito %A Matthew J. Memoli %A Kaitlyn Sadtler %T Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States %D 2021 %R 10.1101/2021.01.27.21250570 %J medRxiv %P 2021.01.27.21250570 %X Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population (n = 11,382) and who had not previously been diagnosed with COVID-19 were selected by quota sampling from 241,424 volunteers (ClinicalTrials.gov NCT04334954). Enrolled participants provided medical, geographic, demographic, and socioeconomic information and 9,028 blood samples. The majority (88.7%) of samples were collected between May 10th and July 31st, 2020. Samples were analyzed via ELISA for anti-Spike and anti-RBD antibodies. Estimation of seroprevalence was performed by using a weighted analysis to reflect the US population. We detected an undiagnosed seropositivity rate of 4.6% (95% CI: 2.6 – 6.5%). There was distinct regional variability, with heightened seropositivity in locations of early outbreaks. Subgroup analysis demonstrated that the highest estimated undiagnosed seropositivity within groups was detected in younger participants (ages 18-45, 5.9%), females (5.5%), Black/African American (14.2%), Hispanic (6.1%), and Urban residents (5.3%), and lower undiagnosed seropositivity in those with chronic diseases. During the first wave of infection over the spring/summer of 2020 an estimate of 4.6% of adults had a prior undiagnosed SARS-CoV-2 infection. These data indicate that there were 4.8 (95% CI: 2.8-6.8) undiagnosed cases for every diagnosed case of COVID-19 during this same time period in the United States, and an estimated 16.8 million undiagnosed cases by mid-July 2020.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04334954Funding StatementThis project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E, 75N91019D00024, Task Order No. 75N91019F00130, Clinical and Translational Science Awards Program grants UL1TR003096 (UAB) and UL1TR001857 (University of Pittsburgh). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Disclaimer: The NIH, its officers, and employees do not recommend or endorse any company, product, or service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study (ClinicalTrials.gov NCT04334954) was approved by the National Institutes of Health Institutional Review Board and conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. All participants provided verbal informed consent prior to enrollment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to corresponding authors on a case-by-case basis as the clinical study is still ongoing. %U https://www.medrxiv.org/content/medrxiv/early/2021/01/31/2021.01.27.21250570.full.pdf